Nonalcoholic fatty liver disease in patients with type 2 diabetes

Clinical Gastroenterology and Hepatology

Volumn 2, Issue 3, 2004, Pages 262-265

  Younossi, Zobair M ^a,c   Gramlich, Terry ^a   Matteoni, Christi A ^a   Boparai, Navdeep ^a   McCullough, Arthur J ^b  

^a LERNER RESEARCH INSTITUTE   (United States)

^b METROHEALTH MEDICAL CENTER   (United States)

^c INOVA FAIRFAX HOSPITAL   (United States)

Author keywords

CI; Confidence interval; Diabetes mellitus; DM; NAFLD; NASH; Nonalcoholic fatty liver disease; Nonalcoholic steatohepatitis; Risk ratio; RR

Indexed keywords

ALBUMIN; ALCOHOL; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; BIOLOGICAL MARKER; GLUCOSE; TRIACYLGLYCEROL;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BODY MASS; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; DISEASE COURSE; DISEASE MARKER; GLUCOSE BLOOD LEVEL; HUMAN; HUMAN TISSUE; LIVER BIOPSY; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; PATHOGENESIS; PROTHROMBIN TIME; RISK FACTOR; TRIACYLGLYCEROL BLOOD LEVEL;

AGE DISTRIBUTION; AGED; ANALYSIS OF VARIANCE; BIOPSY, NEEDLE; CASE-CONTROL STUDIES; COHORT STUDIES; COMORBIDITY; DIABETES MELLITUS, TYPE 2; DISEASE PROGRESSION; FATTY LIVER; FEMALE; HUMANS; INCIDENCE; LIVER CIRRHOSIS; MALE; MIDDLE AGED; PROBABILITY; PROPORTIONAL HAZARDS MODELS; REFERENCE VALUES; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SEX DISTRIBUTION; SURVIVAL ANALYSIS;

EID: 1442299315     PISSN: 15423565     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1542-3565(04)00014-X     Document Type: Article

References (27)

1. Younossi Z.M., Diehl A.M., Ong J.P. Nonalcoholic fatty liver disease an agenda for clinical research. Hepatology. 35:2002;746-752.
2. Mulhall B.P., Ong J.P., Younossi Z.M. Non-alcoholic fatty liver disease an overview. J Gastroenterol Hepatol. 17:2002;1136-1143.
3. Matteoni C.A., Younossi Z.M., Gramlich T., Boparai N., Liu Y.C., McCullough A.J. Nonalcoholic fatty liver disease a spectrum of clinical and pathological severity. Gastroenterology. 116:1999;1413-1419.
4. Falck-Ytter Y., Younossi Z.M., Marchesini G., McCullough A.J. Clinical features and natural history of nonalcoholic steatosis syndromes. Semin Liver Dis. 211:2001;17-26.
5. Lee R.G. Nonalcoholic steatohepatitis a study of 49 patients. Hum Pathol. 20:1989;594-598.
6. Ong J., Younossi Z.M., Reddy V., Price L.L., Gramlich T., Mayes J., Boparai N. Cryptogenic cirrhosis and posttransplantation nonalcoholic fatty liver disease. Liver Transpl. 7:2001;797-801.
7. Powell E.E., Cooksley W.G., Hanson R., Searle J., Halliday J.W., Powell L.W. The natural history of nonalcoholic steatohepatitis a follow-up study of forty-two patients for up to 21 years. Hepatology. 11:1990;74-80.
8. Bacon B.R., Farahvash M.J., Janney C.G., Neuschwander-Tetri B.A. Nonalcoholic steatohepatitis an expanded clinical entity. Gastroenterology. 107:1994;1103-1109.
9. Ratziu V., Bonyhay L., Di Martino V., Charlotte F., Cavallaro L., Sayegh-Tainturier M.H., Giral P., Grimaldi A., Opolon P., Poynard T. Survival, liver failure, and hepatocellular carcinoma in obesity-related cryptogenic cirrhosis. Hepatology. 35:2002;1485-1493.
10. Angulo P., Keach J.C., Batts K.P., Lindor K.D. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology. 306:1999;1356-1362.
11. Dixon J.B., Bhathal P.S., O'Brien P.E. Nonalcoholic fatty liver disease predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. Gastroenterology. 121:2001;91-100.
12. Wanless I.R., Lentz J.S. Fatty liver hepatitis (steatohepatitis) and obesity an autopsy study with analysis of risk factors. Hepatology. 12:1990;1106-1110.
13. Chitturi S., Abeygunasekera S., Farrell G.C., Holmes-Walker J., Hui J.M., Fung C., Karim R., Lin R., Samarasinghe D., Liddle C., Weltman M., George J. NASH and insulin resistance insulin hypersecretion and specific association with the insulin resistance syndrome. Hepatology. 35:2002;373-379.
14. Sanyal A.J., Campbell-Sargent C., Mirshahi F., Rizzo W.B., Contos M.J., Serling R.K., Luketic V.A., Schiffman M.L., Clore J.N. Nonalcoholic steatohepatitis association of insulin resistance. Gastroenterology. 120:2001;1183-1192.
15. Marchesini G., Brizi M., Bianchi G., Tomassetti S., Bugianesi E., Lenzi M., McCullough A.J., Natale S., Forlani G., Melchionda N. Nonalcoholic fatty liver disease a feature of the metabolic syndrome. Diabetes. 50:2001;1844-1850.
16. Le Roith D., Zick Y. Recent advances in our understanding of insulin action and insulin resistance. Diabetes Care. 24:2001;588-597.
17. Matthaei S., Stumvoll M., Kellerer M., Haring H.U. Pathophysiology and pharmacological treatment of insulin resistance. Endocr Rev. 21:2000;585-618.
18. Das U.N. Is obesity an inflammatory condition? Nutrition. 17:2001;953-966.
19. Davis G., Guagnano M.J., Ciabattoni G., Bagili S., Falco A., Marinopiccoli M., Nutini M., Sensi S., Patrono C. Platelet activation in obese women role of inflammation and oxidant stress. JAMA. 228:2002;2008-2014.
20. 22 and platelet activation in diabetes mellitus. Circulation. 99:1999;224-229.
21. Prolisso G., D'Amore A., Volpe C., Balbi V., Saccomanno F., Galzerano D., Giagliano D., Varricchio M., D'Onofri F. Evidence for a relationship between oxidative stress and insulin action in non-insulin dependent (type II) diabetic patients. Metabolism. 43:1994;1426-1429.
22. Evan J.L., Goldfine I.D., Maddux B.A., Grudsky G.M. Oxidate stress and stress-activated signaling pathways a unifying hypothesis of type 2 diabetes. Endocr Rev. 23:2002;599-622.
23. Bonnefont-Rousselot D. Glucose and reactive oxidative species. Curr Opin Clin Nutr Metab Care. 5:2002;561-568.
24. Hube F., Birgel M., Lee Y.M., Hauner H. Expression pattern of tumor necrosis factor receptors in subcutaneous and omental adipose tissue role of obesity and non-insulin dependent diabetes mellitus. Eur J Clin Invest. 29:1999;672-678.
25. Paradis V., Perlemuter G., Bonvoust F., Dargere D., Parfait B., Vidaud M., Conti M., Huet S., Ba N., Buffet C., Bedossa P. High glucose and hyperinsulinemia stimulate connective tissue growth factor expression: a potential mechanism involved in progression to fibrosis in nonalcoholic steatohepatitis. Hepatology. 34:2001;738-744.
26. Younossi Z.M., Gramlich T., Bacon B.R., Matteoni C.A., Boparai N., O'Neill R., McCullough A.J. Hepatic iron and nonalcoholic fatty liver disease. Hepatology. 30:1999;847-850.
27. Ong J.P., Younossi Z.M., Speer C., Olano A., Gramlich T., Boparai N. Chronic hepatitis C and superimposed nonalcoholic fatty liver disease. Liver. 21:2001;266-271.